Expert Opinion on Biological Therapy

Article	Citations
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease	106
Evaluation of physicochemical and biological properties of nonreconstituted MYL-1401O vials, reconstituted MYL-1401O suspension in vial, and diluted MYL-1401O suspension in infusion bags (0.9% saline)	52
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	51
Aflibercept biosimilars – so near, yet so far	50
Antibody drug conjugates for glioblastoma: current progress towards clinical use	45
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	39
Biosimilars and access to biologic therapy in immune-mediated diseases	37
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	37
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	37
The endosomal-lysosomal system in ADC design and cancer therapy	31
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol	30
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	30
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences	30
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies	29
Signaling new therapeutic opportunities: cytokines in prostate cancer	29
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	28
Correction	27
Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing	27
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	22
Long-acting delivery and therapies for neovascular age-related macular degeneration	22
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	21
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors	21
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	21
Correction	20
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	20

Need for a risk-based control strategy for managing glycosylation profile for biosimilar products	19
Strategies for extending the half-life of biotherapeutics: successes and complications	18
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology	18
Moving toward personalized approaches in the management of lupus nephritis	18
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	18
Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in u	17
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents	16
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	16
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	16
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer	15
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	15
Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe	15
A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate P044 with reference medicine in healthy volunteers	15
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective	15
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities	15
Unmet needs in cervical cancer – can biological therapies plug the gap?	15
The nail in psoriatic arthritis: new insights into prognosis and treatment	14
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies	14
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy	14
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives	14
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis	13
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses	13
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma	13
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease	13
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors	13
Management of proctitis in ulcerative colitis and the place of biological therapies	13
Dynamics of biological markets with multiple biosimilar competitors in the United States	13
Where do we stand with radioimmunotherapy for acute myeloid leukemia?	13
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy	13
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children	12
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region	12
Recent advances in delivering RNA-based therapeutics to mitochondria	12
Current status of developing tissue engineering vascular technologies	12
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations	12
Classification and coding of platelet-rich plasma derived from New Zealand white rabbits for tissue engineering and regenerative medicine applications	12
Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?	12
Biological agents targeting interleukin-13 for atopic dermatitis	12
Emerging peptide-based technology for biofilm control	12
An evaluation of pozelimab for the treatment of CHAPLE disease	11
De-escalation of anti-CD20 monoclonal antibody (Rituximab) protocols in Pemphigus Vulgaris – a systematic review	11
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19	11
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project	11
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan	11
Bispecific antibodies for the treatment of breast cancer	11
Efficacy of trastuzumab in HER-2-positive advanced extramammary Paget’s disease	11
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?	11
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward	11
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	10
Personalizing immunotherapy for renal cell carcinoma: how far have we come?	10
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma	10

Belimumab patient profile in Spain: evolution during the last decade and future directions	10
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives	10
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	10
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	10
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	10
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection	10
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	10
Clinical management and innovation in fracture non-union	9
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	9
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms	9
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	9
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	9
Prospects of cell chemotactic factors in bone and cartilage tissue engineering	9
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	9
Harmonizing PD-L1 testing in metastatic triple negative breast cancer	9
Non-traditional approaches for control of antibiotic resistance	9
Treating psoriasis in the elderly: biologics and small molecules	9
Antibody therapeutics for epithelial ovarian cancer	9
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	9
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	9
Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease	9
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	9
Sargramostim in acute radiation syndrome	8
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	8
Correction	8
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	8
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	8
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries	8
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	8
X-linked myotubular myopathy: an untreated treatable disease	8
Epcoritamab in B-cell malignancies: current status and prospects	8
Prostate cancer immunotherapy	8
Ravulizumab for the treatment of myasthenia gravis	8
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	8
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz	8
Rilonacept for the treatment of recurrent pericarditis	8
The global landscape on interchangeability of biosimilars	8
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	8
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	8
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	8
Hemophilia A gene therapy: current and next-generation approaches	8
Biologics in rectal cancer	8
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto	7
Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast	7
Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa	7
CAR T cells for solid tumors – developments to watch in 2023	7
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa	7
Rotavirus vaccines: progress and new developments	7
An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder	7
Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies	7
The future of cellular therapy for the treatment of renal cell carcinoma	7
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease	7
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk	7
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus	7
The future of interleukin gene therapy in head and neck cancers	7
The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?	7
Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy	7
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?	7
Belantamab mafodotin in multiple myeloma	7
Ex vivo gene therapy for lysosomal storage disorders: future perspectives	7
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting	7
An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis	6
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?	6
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress	6
The future of cancer vaccines against colorectal cancer	6
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma	6
Immune checkpoint inhibitors for the treatment of melanoma	6
Biological therapies in patients with liver disease: are they really lifesavers?	6
Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars	6
Non-TNF biologics and their biosimilars in rheumatoid arthritis	6
The future of aptamers in cancer diagnosis, prognosis and treatment	6
Gene therapy for choroideremia: progress, potential and pitfalls	6
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?	6
Current and preclinical treatment options for Merkel cell carcinoma	6
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence	6
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations	6
Treatment options for advanced hepatocellular carcinoma: the potential of biologics	6
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting	6
Applications of mesenchymal stem cells in ocular surface diseases: sources and routes of delivery	6
Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives	6

Literature review and expert opinion on diagnosis and current management of generalized pustular psoriasis	5
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial	5
Perceptions of airway gene therapy for cystic fibrosis	5
Use of rilonacept in patients with recurrent pericarditis during COVID-19 disease	5
Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients?	5
Checkpoint inhibition for early-stage hormone receptor-positive breast cancer	5
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis	5
Correction	5
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma	5
Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group	5
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?	5
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma	5
Therapeutic monoclonal antibodies for COVID-19 management: an update	5
Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center	5
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges	5
Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience	5
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey	5
Pathogenesis-oriented therapy of psoriasis using biologics	5
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas	5
Elotuzumab in multiple myeloma	5
The history of Crohn’s perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel	5
Could siRNA therapeutics change the way we treat dyslipidemia?	5
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients	5
Experts’ review: the emerging roles of romiplostim in immune thrombocytopenia (ITP)	5
Eptinezumab for the treatment of migraine	5
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors	5
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chron	4
Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?	4
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy	4
Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics	4
Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma	4
Short and long-term economic implications of biosimilars	4
Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch	4
Medical students’ knowledge and awareness levels about biologics and biosimilars: the earlier the better?	4
Emerging anti-spike monoclonal antibodies against SARS-CoV-2	4
IL-23 inhibition for the treatment of psoriatic arthritis	4
Platelet-rich therapies as an emerging platform for regenerative medicine	4
Biologics for dengue prevention: up-to-date	4
The evolving therapeutic landscape of diabetic retinopathy	4
Recent developments in CD19-targeted therapies for follicular lymphoma	4
Genetic screening in new onset inflammatory bowel disease during anti-interleukin 17 therapy: unmet needs and call for action	4
Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?	4
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy	4
Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors	4
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement	4
A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers	4
Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects	4
Perispinal etanercept stroke trial design: PESTO and beyond	4
Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis	4
IBD goes home: from telemedicine to self-administered advanced therapies	4
Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer	4
Oncolytic virus therapy for malignant gliomas: entering the new era	4
Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome	4
Addressing practical challenges with bispecific antibody therapy in multiple myeloma	4
Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?	4
Targeting IL-17A for the treatment of pustular psoriasis: a comprehensive review	4
A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence	4
Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus	4
Ranibizumab for the treatment of diabetic retinopathy	4
ANDROMEDA: Dara-VCd for newly diagnosed AL amyloidosis: the next galaxy or a new standard of care?	4
KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine	4
Biosimilars in pediatric rheumatology: innovations, challenges, and opportunities	3
Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi TM ): a multidisciplinary perspective	3
Clinical advances in biological therapy for generalized pustular psoriasis: a review	3
Optimizing the use of vilobelimab for the treatment of COVID-19	3
Chasing optimal first-in-human (FIH) starting dose for biotherapeutics in oncology	3
Regulatory and clinical development to support the approval of advanced therapies medicinal products in Japan	3
Corticosteroids, hyaluronic acid, platelet-rich plasma, and cell-based therapies for knee osteoarthritis - literature trends are shifting in the injectable treatments’ evidence: a systematic review an	3
Next steps for the optimization of exon therapy for Duchenne muscular dystrophy	3
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies	3
Evaluation of canine bone marrow-derived mesenchymal stem cells for experimental full-thickness cutaneous wounds in a diabetic rat model	3
The cell replacement therapeutic potential of human pluripotent stem cells	3
Targeting cervical cancer with anti-PD-1 antibodies: what is new?	3
Challenges and opportunities when transitioning from in vivo gene replacement to in vivo CRISPR/Cas9 therapies – a spotlight on hemophilia	3
Monoclonal antibodies as adjuvant therapies for resected melanoma	3
Mosunetuzumab for the treatment of follicular lymphoma	3
Biological therapies in thrombocytopenia and primary antiphospholipid syndrome: where are we now?	3
Biological therapies for the treatment of psoriasis in pediatrics	3
The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries	3
Advances in biological and targeted therapies for systemic sclerosis	3
Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States	3
Correction	3
Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment	3
Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development	3
Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance	3
Biological therapies for myasthenia gravis	3
Small molecule-regulated switches to provide functional control of CAR T cells within the patient	3
Bispecific antibodies for the treatment of hemophilia A	3
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healt	3
Biologic insights from single-cell studies of psoriasis and psoriatic arthritis	3
Genetic modification and preconditioning strategies to enhance functionality of mesenchymal stromal cells: a clinical perspective	2
Biologic therapy in relapsing polychondritis: navigating between options	2
Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance	2
Treatment of migraine with monoclonal antibodies	2
Luspatercept for β-thalassemia: beyond red blood cell transfusions	2